These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17556027)

  • 1. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review.
    Rostom A; Muir K; Dubé C; Jolicoeur E; Boucher M; Joyce J; Tugwell P; Wells GW
    Clin Gastroenterol Hepatol; 2007 Jul; 5(7):818-28, 828.e1-5; quiz 768. PubMed ID: 17556027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review.
    Hooper L; Brown TJ; Elliott R; Payne K; Roberts C; Symmons D
    BMJ; 2004 Oct; 329(7472):948. PubMed ID: 15475342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evidence-based evaluation of the gastrointestinal safety of coxibs.
    Bombardier C
    Am J Cardiol; 2002 Mar; 89(6A):3D-9D. PubMed ID: 11909555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
    Hsiang KW; Chen TS; Lin HY; Luo JC; Lu CL; Lin HC; Lee KC; Chang FY; Lee SD
    Clin Ther; 2010 Jul; 32(7):1294-303. PubMed ID: 20678677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.
    Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.
    Rostom A; Dubé C; Lewin G; Tsertsvadze A; Barrowman N; Code C; Sampson M; Moher D;
    Ann Intern Med; 2007 Mar; 146(5):376-89. PubMed ID: 17339623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
    Hawkey CJ; Gitton X; Hoexter G; Richard D; Weinstein WM
    Clin Gastroenterol Hepatol; 2006 Jan; 4(1):57-66. PubMed ID: 16431306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
    Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity.
    Yuan JQ; Tsoi KK; Yang M; Wang JY; Threapleton DE; Yang ZY; Zou B; Mao C; Tang JL; Chan FK
    Aliment Pharmacol Ther; 2016 Jun; 43(12):1262-75. PubMed ID: 27121479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors.
    Rostom A; Muir K; Dube C; Lanas A; Jolicoeur E; Tugwell P
    Drug Healthc Patient Saf; 2009; 1():47-71. PubMed ID: 21701610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
    Mallen SR; Essex MN; Zhang R
    Curr Med Res Opin; 2011 Jul; 27(7):1359-66. PubMed ID: 21561397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis.
    Ramey DR; Watson DJ; Yu C; Bolognese JA; Curtis SP; Reicin AS
    Curr Med Res Opin; 2005 May; 21(5):715-22. PubMed ID: 15974563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trials of COX-2 inhibitors: an analysis of doses used and trends over time to investigate implications for comparative safety.
    Stefansdottir G; De Bruin ML; Knol MJ; Grobbee DE; Leufkens HG
    Drug Saf; 2011 Sep; 34(9):783-92. PubMed ID: 21830840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA; Derry S; McQuay HJ
    BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis.
    Jarupongprapa S; Ussavasodhi P; Katchamart W
    J Gastroenterol; 2013 Jul; 48(7):830-8. PubMed ID: 23208017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global gastrointestinal safety profile of etoricoxib and lumiracoxib.
    Yuan Y; Hunt RH
    Curr Pharm Des; 2007; 13(22):2237-47. PubMed ID: 17691997
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.